Applications for Methotrexate Optimization in Rheumatoid Arthritis

NCT ID: NCT01038349

Last Updated: 2011-06-02

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 256 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-06-30
• Study Completion Date: 2010-02-28

Brief Summary

The goal of this study is to enable the study sponsor to assess the impact of a marketed or validated blood test has on physicians' clinical treatment decision making when treating RA patients who have been taking methotrexate.

Ultimately, the blood test will allow treating physicians to modify current methotrexate therapy in partially responding Rheumatoid Arthritis (RA) patients' therapy, on an individualized basis, as a means of improving clinical outcomes.

The study requires a blood sample from RA patients who have been on methotrexate therapy for a minimum of 3 months and are having an inadequate response to therapy. Physicians will then be provided with the results of the test indicating the methotrexate polyglutamate (active metabolites of methotrexate) levels in the patient's red blood cells as a means to help determine whether a patient's exposure to methotrexate has been optimized.

Detailed Description

This study is currently enrolling individuals who have an established diagnosis of RA and are receiving methotrexate as part of their therapy. Patients are required to submit a blood sample. There is no cost to volunteers who participate.

Conditions

Rheumatoid Arthritis

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

Avise PG - Diagnostic test

Eligible patients will receive an Avise PG test

Intervention Type: OTHER

Other Intervention Names

Measure of methotrexate polyglutamates test

Eligibility Criteria

Inclusion Criteria

• Able to read, understand, and sign the informed consent form
• Able to read, write, and speak English
• ≥18 years of age
• Diagnosed with RA within past 24 months (waiver)
• Taking oral methotrexate therapy for a minimum of 3 months
• Considered to have an insufficient response to methotrexate and therefore a candidate for change to therapy, including changing MTX dose or changing route of delivery, or adding or switching DMARDs (including but not limited to biologic DMARDs)

Exclusion Criteria

• Prior exposure of the study center, study physician or study patient to the Avise PG laboratory test
• Patients with known abnormal hepatic and or hematological parameters
• Use of prednisone >10mg/day (or its equivalent)
• Rheumatologic diagnosis other than primary RA

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cypress Bioscience, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Cypress Bioscience, Inc

Principal Investigators

R. Michael Gendreau, M.D., Ph.D.

Role: STUDY_DIRECTOR

Cypress Bioscience, Inc.

Other Identifiers

CYP-D-001

Identifier Type: -

Identifier Source: org_study_id